CARGO Therapeutics (CRGX) Expected to Announce Earnings on Monday

Key Points

• CARGO Therapeutics is set to announce its Q2 2025 earnings results on August 11, with analysts predicting an earnings per share of ($0.42).
• The stock has seen a recent trading price of $4.48, with a market capitalization of $206.34 million and a 12-month trading range of $3.00 to $25.45.
• Invesco Ltd. has significantly increased its stake in CARGO Therapeutics by 146.9%, holding approximately 0.06% of the company, indicating strong institutional interest.

CARGO Therapeutics (NASDAQ:CRGX - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect CARGO Therapeutics to post earnings of ($0.42) per share for the quarter.

CARGO Therapeutics Trading Down 0.3%

NASDAQ:CRGX opened at $4.48 on Monday. The company has a market capitalization of $206.34 million, a P/E ratio of -0.97 and a beta of 0.30. CARGO Therapeutics has a 12 month low of $3.00 and a 12 month high of $25.45. The business's 50-day moving average is $4.42 and its 200 day moving average is $4.75.

Analysts Set New Price Targets

Separately, Jefferies Financial Group boosted their target price on CARGO Therapeutics from $3.70 to $5.00 and gave the stock a "hold" rating in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $15.40.

Hedge Funds Weigh In On CARGO Therapeutics

An institutional investor recently raised its position in CARGO Therapeutics stock. Invesco Ltd. increased its position in CARGO Therapeutics, Inc. (NASDAQ:CRGX - Free Report) by 146.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,266 shares of the company's stock after acquiring an additional 16,818 shares during the period. Invesco Ltd. owned approximately 0.06% of CARGO Therapeutics worth $115,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 93.16% of the stock is owned by institutional investors.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.